search
Back to results

Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 3
Locations
Russian Federation
Study Type
Interventional
Intervention
Gosogliptin
Vildagliptin
Metformin
Sponsored by
SatRx LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

18 Years - 78 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Men and women from 18 through 78 years
  2. Confirmed clinical diagnosis of type 2 diabetes mellitus
  3. Drug-naive patients or patients without hypoglycemic drug treatment at least till 12 weeks before screening
  4. Patient's agreed to use adequate methods of contraception during the study
  5. Body mass index 22-40 kg/m2
  6. HbA1c 7.5 - 11.0%
  7. FPG < 15 mmol/L
  8. Signed informed consent
  9. Patient's ability to follow all protocol requirements

Exclusion Criteria:

  1. Pregnancy and lactation, women who plan to become pregnant during the clinical study, women of child-bearing potential (i.e. non-stylized surgically and in period of post menopause less than 2 years) without adequate methods of contraception.
  2. History of type 1 diabetes mellitus and other forms
  3. Severe metabolic complications of diabetes as ketoacidosis, hyperosmolar coma during 6 weeks before screening
  4. Severe complication of diabetes, for instance proliferative retinopathy in active stage, autonomic neuropathy or gastroparesis
  5. A known allergy, hypersensitivity or contraindications to Gosogliptin, Vildagliptin, Metformin or their components
  6. Convulsive disorder; system autoimmune diseases or vascular collagenosis demanding the previous or current treatment by systemic corticosteroids, cytostatics; malignancy within the last 5 years (except for a basal-cell carcinoma);
  7. Significant cardiovascular diseases within 12 months of screening including: chronic heart failure of a class III or IV (NYHA), severe arrhythmia demanding treatment with antiarrhythmics, unstable angina, myocardial infarction, heart and coronary vessels surgery, heart valves diseases, transitory ischaemic attack or stroke, uncontrolled arterial hypertension with systolic Blood Pressure > 180 mm Hg and diastolic Blood Pressure > 110 mm Hg, pulmonary embolism or deep venous thrombosis
  8. A nephrotic syndrome, a chronic renal failure, serum creatinine > 1.5 mg/dL (132 µmol/L) in men and > 1.4 mg/dL (123 µmol/L) in women or GFR <60 ml/min/1.73m2
  9. HBV, HCV or a liver cirrhosis; AST or ALT > 3 ULN; total bilirubin > 2 ULN
  10. HIV; severe infection that can affect glycemia within 30 days of screening
  11. Anemia (Hb ≤10.5 g/dL in women or ≤11.5 g/dL in men); loss of > 1 unit of blood ( 500 mL) or blood transfusion within 12 weeks of screening
  12. Drugs or alcohol abuse
  13. Administration of any study drug within 30 days of screening
  14. Inability to read or write; unwillingness to understand and follow the protocol procedures

Sites / Locations

  • Non-state healthcare Organization "Road Clinical Hospital at the station Chelyabinsk Open Joint Stock Company" Russian Railways
  • State Budget Healthcare Institution of Moscow "Endocrinology Dispensary"
  • SEI HPE "First Moscow State Medical University n.a. I.M. Sechenov of Ministry of Health and Social Development of the Russian Federation", Chair of faculty therapy #2 based at SHI of Moscow "City clinical hospital #61"
  • State Budget Educational Institution higher professional education "1st Moscow State Medical University n.a. I.M. Sechenov of the Ministry of Healthcare of Russian Federation"
  • Federal State Institution "Clinical Hospital № 1" of the Office of the President of the Russian Federation
  • State Budget Healthcare Institution of Moscow city "City Clinical Hospital # 71 by the Department of Healthcare in Moscow"
  • State Budget Educational Institution of higher professional education "1st Moscow State Medical University n.a. I.M. Sechenov of the Ministry of Healthcare of Russian Federation" based on Endocrinology department of Hospital № 67 n.a L A Vorohobova
  • SEI APE "Russian Medical Academy of Postgraduate Education of Roszdrav", Chair of endocrinology and diabetology with course of endocrine surgery based at FSI "Central Clinical hospital of civil aviation"
  • State budgetary institution "Nizhny Novgorod Regional Clinical Hospital n.a Semashko
  • State Health Care Institution "Perm Regional Hospital for War Veterans"
  • State Educational Institution of Higher Professional Education "Perm State Medical Academy n.a. academician EA Wagner's "Ministry of Health of the Russian Federation on the basis of Department of Endocrinology Regional Clinical Hospital
  • SHI "Republic Hospital n.a. V.A. Baranov"
  • State budgetary institution of Ryazan region "City Clinical Hospital № 11"
  • St. Petersburg State healthcare institution "City Outpatient Clinic #37"
  • FSHI "Clinical Hospital #122 n.a. L.G. Sokolov of FMBA of Russia", Internal medicine department
  • State Health Care Institution Leningrad Regional Hospital
  • Autonomous Noncommercial Organization "Medical Centre "XXI сentury"
  • St. Petersburg State healthcare institution "City Hospital of Saint Martyr Elizaveta"
  • FSMEI HPE "Military Medical Academy n.a. S.M. Kirov" of the Ministry of Defence of the Russian Federation, 1st Internal medicine Chair of advanced training
  • "Diabetes Center "LLC
  • State Budget Educational Institution higher professional education "Saratov State Medical University n.a. V.I. Razumovsky" of the Ministry of Healthcare of Russian Federation based on Clinical Hospital n.a S.R. Mirotvortsev
  • Municipal health care institution "City polyclinic №20
  • SBEI HPE "Smolensk State Medical Academy" of the Ministry of Health and Social Development of the Russian Federation, Center of clinical research of diagnostic and medicinal products, Chair of clinical pharmacology
  • State budget educational institution of higher education "Smolensk State Medical Academy," of Ministry of Health and Social Development of the Russian Federation on the basis of sanatorium SSMA
  • State autonomous healthcare institution of Yaroslavl Region "Сlinical hospital for emergency medical care n. a. N.V. Solovyov"
  • Municipal clinical health institution Health Service Novo-Yaroslavl Oil Refinery
  • SHI of Yaroslavl region "Regional Clinical Hospital", Endocrinology department

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Gosogliptin treatment group

Vildagliptin treatment group

Arm Description

12 weeks of monotherapy and 24 weeks of combination with Metformin

12 weeks of monotherapy and 24 weeks of combination with Metformin

Outcomes

Primary Outcome Measures

Mean change of HbA1c
Gosogliptin treatment group vs. Vildagliptin treatment group

Secondary Outcome Measures

HbA1c level of ≤7%
Percent of patients who reach the target HbA1c
Hypoglycemic episodes
Incidence of hypoglycemic episodes during the monotherapy and in combination with Metformin
Fasting plasma glucose
Change of fasting plasma glucose from baseline
Change of Body Mass
Change of Body Mass from baseline
Adverse event
AE rate

Full Information

First Posted
March 18, 2017
Last Updated
March 18, 2017
Sponsor
SatRx LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT03088670
Brief Title
Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.
Official Title
Evaluate Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
April 23, 2013 (Actual)
Primary Completion Date
March 30, 2014 (Actual)
Study Completion Date
October 3, 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
SatRx LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To demonstrate that efficacy of Gosogliptin as Monotherapy and in Combination with Metformin is non-inferior to efficacy of Vildagliptin as Monotherapy and in combination with Metformin in the effects on glycosilated hemoglobin (HbA1c) at Week 12 and Week 36 compared to baseline (Week 0).
Detailed Description
Screening of patients at Week -2 Training for all complying patients in Diabetes Program School at Week -1 with glucometer and patient diary distribution for SMBG Randomization in one of two groups in the ratio 1:1. The 1st stage includes 12 weeks of monotherapy with Gosogliptin or Vildagliptin. The 2nd stage includes 24 weeks of combination therapy with Gosogliptin and Metformin or Vildagliptin and Metformin. Follow-up period of 4 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
299 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Gosogliptin treatment group
Arm Type
Experimental
Arm Description
12 weeks of monotherapy and 24 weeks of combination with Metformin
Arm Title
Vildagliptin treatment group
Arm Type
Active Comparator
Arm Description
12 weeks of monotherapy and 24 weeks of combination with Metformin
Intervention Type
Drug
Intervention Name(s)
Gosogliptin
Intervention Description
20 mg per day, dose titration to 30 mg per day at Week 4 as required Administration: orally
Intervention Type
Drug
Intervention Name(s)
Vildagliptin
Intervention Description
50 mg per day, dose titration to 100 mg per day at Week 4 as required (50 mg twice a day) Administration: orally
Intervention Type
Drug
Intervention Name(s)
Metformin
Intervention Description
1000 mg per day starting Week 12 (500 mg twice a day), dose titration to 2000 mg per day at Week 16 as required (1000 mg twice a day). Administration: orally
Primary Outcome Measure Information:
Title
Mean change of HbA1c
Description
Gosogliptin treatment group vs. Vildagliptin treatment group
Time Frame
at Weeks 12 and 36 from baseline
Secondary Outcome Measure Information:
Title
HbA1c level of ≤7%
Description
Percent of patients who reach the target HbA1c
Time Frame
at Weeks 12 and 36 from baseline
Title
Hypoglycemic episodes
Description
Incidence of hypoglycemic episodes during the monotherapy and in combination with Metformin
Time Frame
up to 36 week
Title
Fasting plasma glucose
Description
Change of fasting plasma glucose from baseline
Time Frame
at Weeks 12 and 36
Title
Change of Body Mass
Description
Change of Body Mass from baseline
Time Frame
at Weeks 12 and 36
Title
Adverse event
Description
AE rate
Time Frame
up to 40 week

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
78 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men and women from 18 through 78 years Confirmed clinical diagnosis of type 2 diabetes mellitus Drug-naive patients or patients without hypoglycemic drug treatment at least till 12 weeks before screening Patient's agreed to use adequate methods of contraception during the study Body mass index 22-40 kg/m2 HbA1c 7.5 - 11.0% FPG < 15 mmol/L Signed informed consent Patient's ability to follow all protocol requirements Exclusion Criteria: Pregnancy and lactation, women who plan to become pregnant during the clinical study, women of child-bearing potential (i.e. non-stylized surgically and in period of post menopause less than 2 years) without adequate methods of contraception. History of type 1 diabetes mellitus and other forms Severe metabolic complications of diabetes as ketoacidosis, hyperosmolar coma during 6 weeks before screening Severe complication of diabetes, for instance proliferative retinopathy in active stage, autonomic neuropathy or gastroparesis A known allergy, hypersensitivity or contraindications to Gosogliptin, Vildagliptin, Metformin or their components Convulsive disorder; system autoimmune diseases or vascular collagenosis demanding the previous or current treatment by systemic corticosteroids, cytostatics; malignancy within the last 5 years (except for a basal-cell carcinoma); Significant cardiovascular diseases within 12 months of screening including: chronic heart failure of a class III or IV (NYHA), severe arrhythmia demanding treatment with antiarrhythmics, unstable angina, myocardial infarction, heart and coronary vessels surgery, heart valves diseases, transitory ischaemic attack or stroke, uncontrolled arterial hypertension with systolic Blood Pressure > 180 mm Hg and diastolic Blood Pressure > 110 mm Hg, pulmonary embolism or deep venous thrombosis A nephrotic syndrome, a chronic renal failure, serum creatinine > 1.5 mg/dL (132 µmol/L) in men and > 1.4 mg/dL (123 µmol/L) in women or GFR <60 ml/min/1.73m2 HBV, HCV or a liver cirrhosis; AST or ALT > 3 ULN; total bilirubin > 2 ULN HIV; severe infection that can affect glycemia within 30 days of screening Anemia (Hb ≤10.5 g/dL in women or ≤11.5 g/dL in men); loss of > 1 unit of blood ( 500 mL) or blood transfusion within 12 weeks of screening Drugs or alcohol abuse Administration of any study drug within 30 days of screening Inability to read or write; unwillingness to understand and follow the protocol procedures
Facility Information:
Facility Name
Non-state healthcare Organization "Road Clinical Hospital at the station Chelyabinsk Open Joint Stock Company" Russian Railways
City
Chelyabinsk
ZIP/Postal Code
454048
Country
Russian Federation
Facility Name
State Budget Healthcare Institution of Moscow "Endocrinology Dispensary"
City
Moscow
ZIP/Postal Code
119034
Country
Russian Federation
Facility Name
SEI HPE "First Moscow State Medical University n.a. I.M. Sechenov of Ministry of Health and Social Development of the Russian Federation", Chair of faculty therapy #2 based at SHI of Moscow "City clinical hospital #61"
City
Moscow
ZIP/Postal Code
119048
Country
Russian Federation
Facility Name
State Budget Educational Institution higher professional education "1st Moscow State Medical University n.a. I.M. Sechenov of the Ministry of Healthcare of Russian Federation"
City
Moscow
ZIP/Postal Code
119435
Country
Russian Federation
Facility Name
Federal State Institution "Clinical Hospital № 1" of the Office of the President of the Russian Federation
City
Moscow
ZIP/Postal Code
121352
Country
Russian Federation
Facility Name
State Budget Healthcare Institution of Moscow city "City Clinical Hospital # 71 by the Department of Healthcare in Moscow"
City
Moscow
ZIP/Postal Code
121374
Country
Russian Federation
Facility Name
State Budget Educational Institution of higher professional education "1st Moscow State Medical University n.a. I.M. Sechenov of the Ministry of Healthcare of Russian Federation" based on Endocrinology department of Hospital № 67 n.a L A Vorohobova
City
Moscow
ZIP/Postal Code
123423
Country
Russian Federation
Facility Name
SEI APE "Russian Medical Academy of Postgraduate Education of Roszdrav", Chair of endocrinology and diabetology with course of endocrine surgery based at FSI "Central Clinical hospital of civil aviation"
City
Moscow
ZIP/Postal Code
125367
Country
Russian Federation
Facility Name
State budgetary institution "Nizhny Novgorod Regional Clinical Hospital n.a Semashko
City
Nizhny Novgorod
ZIP/Postal Code
603126
Country
Russian Federation
Facility Name
State Health Care Institution "Perm Regional Hospital for War Veterans"
City
Perm
ZIP/Postal Code
614097
Country
Russian Federation
Facility Name
State Educational Institution of Higher Professional Education "Perm State Medical Academy n.a. academician EA Wagner's "Ministry of Health of the Russian Federation on the basis of Department of Endocrinology Regional Clinical Hospital
City
Perm
ZIP/Postal Code
614990
Country
Russian Federation
Facility Name
SHI "Republic Hospital n.a. V.A. Baranov"
City
Petrozavodsk
ZIP/Postal Code
185019
Country
Russian Federation
Facility Name
State budgetary institution of Ryazan region "City Clinical Hospital № 11"
City
Ryazan
ZIP/Postal Code
390037
Country
Russian Federation
Facility Name
St. Petersburg State healthcare institution "City Outpatient Clinic #37"
City
Saint Petersburg
ZIP/Postal Code
191119
Country
Russian Federation
Facility Name
FSHI "Clinical Hospital #122 n.a. L.G. Sokolov of FMBA of Russia", Internal medicine department
City
Saint Petersburg
ZIP/Postal Code
194291
Country
Russian Federation
Facility Name
State Health Care Institution Leningrad Regional Hospital
City
Saint Petersburg
ZIP/Postal Code
194291
Country
Russian Federation
Facility Name
Autonomous Noncommercial Organization "Medical Centre "XXI сentury"
City
Saint Petersburg
ZIP/Postal Code
194354
Country
Russian Federation
Facility Name
St. Petersburg State healthcare institution "City Hospital of Saint Martyr Elizaveta"
City
Saint Petersburg
ZIP/Postal Code
195257
Country
Russian Federation
Facility Name
FSMEI HPE "Military Medical Academy n.a. S.M. Kirov" of the Ministry of Defence of the Russian Federation, 1st Internal medicine Chair of advanced training
City
Saint Petersburg
ZIP/Postal Code
198013
Country
Russian Federation
Facility Name
"Diabetes Center "LLC
City
Samara
ZIP/Postal Code
443041
Country
Russian Federation
Facility Name
State Budget Educational Institution higher professional education "Saratov State Medical University n.a. V.I. Razumovsky" of the Ministry of Healthcare of Russian Federation based on Clinical Hospital n.a S.R. Mirotvortsev
City
Saratov
ZIP/Postal Code
, 410054
Country
Russian Federation
Facility Name
Municipal health care institution "City polyclinic №20
City
Saratov
ZIP/Postal Code
410018
Country
Russian Federation
Facility Name
SBEI HPE "Smolensk State Medical Academy" of the Ministry of Health and Social Development of the Russian Federation, Center of clinical research of diagnostic and medicinal products, Chair of clinical pharmacology
City
Smolensk
ZIP/Postal Code
214019
Country
Russian Federation
Facility Name
State budget educational institution of higher education "Smolensk State Medical Academy," of Ministry of Health and Social Development of the Russian Federation on the basis of sanatorium SSMA
City
Smolensk
ZIP/Postal Code
214019
Country
Russian Federation
Facility Name
State autonomous healthcare institution of Yaroslavl Region "Сlinical hospital for emergency medical care n. a. N.V. Solovyov"
City
Yaroslavl
ZIP/Postal Code
150003
Country
Russian Federation
Facility Name
Municipal clinical health institution Health Service Novo-Yaroslavl Oil Refinery
City
Yaroslavl
ZIP/Postal Code
150023
Country
Russian Federation
Facility Name
SHI of Yaroslavl region "Regional Clinical Hospital", Endocrinology department
City
Yaroslavl
ZIP/Postal Code
150062
Country
Russian Federation

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.

We'll reach out to this number within 24 hrs